Praxis Precision Medicine Bolsa (NASDAQ: PRAX)

Últimas noticias sobre Praxis Precision Medicine (NASDAQ:PRAX) Bolsa

PRAXIS PRECISION MEDICINES I

Praxis Precision Medicine

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicines Inc

Praxis Funds Praxis Impact Large Cap Growth ETF

Praxis Funds Praxis Impact Large Cap Value ETF

Praxsyn Corp

On Tuesday, Sen. Bernie Sanders (I-Vt) delivered a sharp critique of the Republican budget reconciliation bill, denouncing it as a &#8220;death sentence&#8221; for millions of Americans.
What Happened: Sanders accused President Donald Trump and congressional Republicans of pushing through what he called a "disastrous" budget bill that offers a $235 billion estate tax break to the wealthiest 0.2% of Americans—those inheriting over $30 million—while leaving 99.8% of citizens with no benefit.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="BREAKING: Bernie Sanders Absolutely Torches GOP Reconciliation Budget Bill, Warns Of Mediciad Cuts" width="500" height="281" src="https://www.youtube.com/embed/8YAg1_r1e4A?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The bill would also slash $715 billion from Medicaid and the Affordable Care Act, <a href="https://www.benzinga.com/general/health-care/25/05/45345409/trumps-big-beautiful-bill-banks-on-huge-medicaid-cuts-as-its-cost-saving-centerpiece-see-who-risks-losing-coverage-under-the-gop-proposal">taking health insurance away from over 13.7 million people</a>, he said. Additionally, "this legislation would provide a $420 billion tax break to large, profitable corporations that are stashing their profits in the Cayman Islands and other offshore tax havens and who, by the way, are replacing American workers with robots."
Programs in education, nutrition, and Planned Parenthood would also face huge cuts, he noted, "at a time when we already spend more on the military than the next nine nations combined and when everyone knows there is massive waste and fraud in the Pentagon, this bill increases defense spending by $150 billion."
See Also: <a href="https://www.benzinga.com/25/05/45417759/trump-says-hes-ok-with-tiny-tax-hikes-for-the-rich-but-warns-republicans-there-will-be-political-backlash">Trump Says He&#8217;s OK With &#8216;Tiny&#8217; Tax Hikes For The Rich, But Warns Republicans There Will Be Political Backlash</a>
Why It Matters: Sanders warned the bill "does exactly the opposite of what should be done," particularly during a time of historic wealth inequality. He pointed to data from the RAND Corporation demonstrating that the top 1% own more wealth than the bottom 93% and that $80 trillion has been redistributed from the bottom 90% to the top 1% over the past 50 years. "This legislation makes the rich and wealthy campaign contributors even richer while making life harder and more stressful for the working families of our country," he said. Sanders criticized the bill for forcing low-income Americans to pay unaffordable co-pays and gutting Medicaid funding, which he said would result in the death of "many thousands more Americans."
In his closing remarks, Sanders called the bill a stark example of a corrupt political system serving billionaire donors at the expense of everyday Americans. "At a time when children and seniors go hungry here in the wealthiest country on Earth," he said, "our job should be to make sure that all Americans have the nutrition they need to lead healthy lives—not increase the level of hunger."
Sanders is among many politicians who are opposed to the provisions of the bill. Rep. John Larson (D-Conn.) raised questions about whether the bill lives up to President Trump&#8217;s promise of <a href="https://www.benzinga.com/general/health-care/25/05/45431505/gop-tax-bill-breaks-trumps-social-security-tax-pledge-still-hits-25-million-seniors-while-elon-musks-stock-wealth-skirts-fica">no taxes on Social Security</a> during a Ways and Means Committee meeting, while other Democrats have called on GOP leaders to discard Medicaid cuts and instead <a href="https://www.benzinga.com/general/health-care/25/05/45313228/democrats-urge-gop-to-target-medicare-advantage-upcoding-instead-of-medicaid-cuts-calling-budget-plan-a-man-made-disaster" target="_blank" rel="noreferrer noopener">address Medicare Advantage "upcoding"</a> to tackle federal waste.
Read Next: <a href="https://www.benzinga.com/general/space/25/05/45430526/as-elon-musk-secures-saudi-starlink-deal-elizabeth-warren-and-senate-democrats-demand-probe-into-possible-ethics-violations-and-accuse-trump-administration-of-helping-spacex-secure-foreign-deals">As Elon Musk Secures Saudi Starlink Deal, Elizabeth Warren And Senate Democrats Demand Probe Into Possible Ethics Violations And Accuse Trump Administration Of Helping SpaceX Secure Foreign Deals</a>

Government

News

Health Care

Politics

Personal Finance

General

Bernie Sanders Calls Trump's 'Big Beautiful Bill' A 'Death Sentence,' Says It Delivers $235 Billion Tax Break To Top 0.2%—While 99.8% Of Americans Get Nothing

WIIM

ANTA

Antalpha Platform shares are trading higher amid possible continued strength its initial public offering that took place Wednesday.

Benchmark analyst Mark Zgutowicz maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Buy and lowers the price target from $55 to $52.

Price Target

Analyst Ratings

GLBE

Benchmark Maintains Buy on Global E Online, Lowers Price Target to $52

IBTA

Ibotta shares are trading higher after the company reported better-than-expected Q1 financial results and Needham raised its price target on the stock from $60 to $70.

TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(2.00) by 25.5 percent. This is a 88.24 percent increase over losses of $(21.35) per share from the same period last year.

Earnings

Earnings Misses

RNAZ

Reported May 14, 2025: TransCode Therapeutics Q1 EPS $(2.51) Misses $(2.00) Estimate

Barclays analyst Jiong Shao maintains Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) with a Overweight and raises the price target from $182 to $200.

Barclays Maintains Overweight on Sea, Raises Price Target to $200

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/quote/NEXN/earnings">first quarter on Wednesday</a>.
The company posted quarterly earnings of 16 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $78.33 million which beat the analyst consensus estimate of $76.60 million.
&#8220;Our momentum continued in Q1 fueling record results driven by CTV, alongside significant Adjusted EBITDA growth,&#8221; said Ofer Druker, Chief Executive Officer of Nexxen. &#8220;We believe these results reflect the payoff from years of investment in our technology, data capabilities and brand. Industry partners are increasingly embracing our full stack of interconnected AI-powered data and technology solutions &#8211; driving greater spending, deeper adoption and long-term growth potential, even in uncertain market conditions.&#8221;
Nexxen shares fell 5.7% to close at $11.62 on Wednesday.
These analysts made changes to their price targets on Biodesix following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Laura Martin maintained Nexxen International with a Buy and raised the price target from $12 to $14.</li>
<li>Rosenblatt analyst Barton Crockett maintained the stock with a Buy and raised the price target from $15 to $16.</li>
<li>JMP Securities analyst Matthew Condon maintained the stock with a Market Outperform and raised the price target from $11 to $15.</li>
</ul>
Considering buying CL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/4011d15f-e260-4f74-87ae-27141197fbc9" alt="" style="width:664px;height:auto" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

NEXN

Nexxen International Analysts Boost Their Forecasts After Upbeat Q1 Results

Barclays analyst Raimo Lenschow maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Overweight and raises the price target from $55 to $62.

Barclays Maintains Overweight on Dynatrace, Raises Price Target to $62

POAI

Predictive Oncology shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

APRE

Aprea Therapeutics shares are trading higher on continued strength after the company reported a year-over-year increase in Q1 EPS results on Wednesday..

Barclays analyst Raimo Lenschow maintains CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Overweight and raises the price target from $60 to $70.

CRWV

Barclays Maintains Overweight on CoreWeave, Raises Price Target to $70

Biotech

SELLAS Life Sciences Doses First Pediatric AML Patient In Ongoing Phase 2 Trial Of SLS009 r/r AML

CETX

Cemtrex Q2 EPS $4.10, Sales $27.25M Up From $17.16M YoY

LAZR

Luminar Technologies shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral.

Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) shares rocketed premarket on Thursday after the company disclosed a definitive deal to be acquired by Dick&#8217;s Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>), which values Foot Locker&#8217;s equity at around $2.4 billion and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431136/dicks-sporting-goods-to-acquire-foot-locker-to-create-a-global-leader-in-the-sports-retail-industr" rel="noreferrer noopener">its enterprise at about $2.5 billion</a>.
DICK&#8217;S plans to fund the acquisition using a combination of its existing cash reserves and newly incurred debt.
As per the deal, Foot Locker shareholders will have the option to receive either $24.00 in cash or 0.1168 shares of DICK&#8217;S common stock for each share of Foot Locker common stock they own.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/sports/25/05/45424475/foot-locker-stock-soars-on-potential-dicks-sporting-goods-deal-report" rel="noreferrer noopener">Foot Locker Stock Soars On Potential Dick&#8217;s Sporting Goods Deal: Report</a>
Based on Foot Locker&#8217;s closing stock price on May 14, 2025, the $24.00 per-share consideration reflects a premium of about 66% over Foot Locker&#8217;s 60-trading-day volume-weighted average price.
The transaction is expected to close in the second half of 2025, upon shareholder approval and other customary closing conditions.
Synergy &amp; Benefits: DICK&#8217;S anticipates that this acquisition to increase its EPS starting in the first full fiscal year after the deal closes, excluding transaction and other one-time costs related to achieving synergies.
The company also expects to realize between $100 million and $125 million in cost synergies in the medium term through efficiencies in <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">procurement and direct sourcing</a>.
Ed Stack, Executive Chairman of DICK&#8217;S said, &#8220;By applying our operational expertise to this iconic business, we see a clear path to further unlocking growth and enhancing Foot Locker&#8217;s position in the industry. Together, we will leverage the complementary strengths of both organizations to better serve the broad and evolving needs of global sports retail consumers.&#8221;
Mary Dillon, CEO of Foot Locker added, &#8220;By joining forces with DICK&#8217;S, Foot Locker will be even better positioned to expand sneaker culture, elevate the omnichannel experience for our customers and brand partners, and enhance our position in the industry.&#8221;
DKS Q1 Preliminary: The company sees comparable sales growth of 4.5% and adjusted EPS of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431210/dicks-sporting-goods-reports-preliminary-results-for-first-quarter-of-2025-reports-comparable-sale" rel="noreferrer noopener">$3.37 vs. the consensus of&nbsp;$3.22</a>. The company will report first-quarter <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">results&nbsp;on&nbsp;May 28, 2025</a>.
FL Q1 Preliminary: The company expects a comparable sales decline of 2.6% year over year (Y/Y), with comparable sales in the&nbsp;North <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431211/foot-locker-inc-reports-preliminary-first-quarter-2025-financial-results" rel="noreferrer noopener">America&nbsp;region decreasing by 0.5%</a>.
Foot Locker projects adjusted loss per share of&nbsp;7 cents&nbsp;in the first quarter (consensus of $0.41), vs. EPS of&nbsp;22&nbsp;cents in the corresponding prior-year period.
Adjusted loss per share excludes non-cash impairment charges totaling&nbsp;$276 million&nbsp;and reflects a&nbsp;$140 million&nbsp;charge related to a&nbsp;tradename and a goodwill impairment charge of&nbsp;$110 million.
Also, the company recorded a full valuation allowance on deferred tax assets and deferred tax costs related to the European business totaling&nbsp;$124 million.
Foot Locker will report results on May 29, 2025.
As of February&nbsp;1, 2025, DICK&#8217;S cash and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44242779/dicks-sporting-goods-reports-fourth-quarter-and-full-year-2024-results-delivers-largest-sales-quar" rel="noreferrer noopener">cash equivalents stood at $1.69 billion</a>.
Price Action: FL shares are up 83.30% at $23.59, while DKS stock dipped 11.70% at $185.10&nbsp;premarket at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/04/44672618/trump-tariffs-to-hurt-nike-under-armour-vf-are-ralph-lauren-foot-locker-safer-bets" target="_blank" rel="noreferrer noopener">Trump Tariffs To Hurt Nike, Under Armour, VF: Are Ralph Lauren, Foot Locker Safer Bets?</a></li>
</ul>
Photo by C. Nass via Shutterstock

Large Cap

Guidance

Movers

Dick's Sporting Goods To Acquire Foot Locker At 66% Premium

Bitcoin Depot shares are trading higher after the company reported a year-over-year increase in Q1 EPS results and better-than-expected sales results.

Barclays analyst Tim Long maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Equal-Weight and raises the price target from $61 to $66.

CSCO

Barclays Maintains Equal-Weight on Cisco Systems, Raises Price Target to $66

April retail sales data showed that the <a href="https://www.benzinga.com/topic/tariffs">round of tariffs</a> announced by President Donald Trump on &#8220;Liberation Day&#8221; started to produce their effects by reducing household consumption.
However, while households reined in spending, inflationary pressures at the producer level unexpectedly contracted in April, notching the biggest decline since April 2020 and highlighting the disinflationary impact of tariffs on input costs across industries.
U.S. retail sales grew only by 0.1% in April from the previous month, a report from the Census Bureau showed Thursday. The outcome marks a sharp reversal from March's upwardly revised 1.7% gain, yet slightly topped economist expectations of no change.
A relevant drag came from motor vehicles and parts which contracted by 0.1%. In March, auto-related sales jumped 5.5% as consumers rushed to buy before tariffs took effect. 
Stripping out autos, retail sales also rose 0.1%, a slowdown from March's 0.8% increase and below the 0.3% consensus. 
When excluding both gasoline and autos, the figure improves slightly to a 0.2% rise, though it still marks a deceleration from March's 1.1% growth.
On an annual basis, April retail sales were up 5.2% from a year earlier, unchanged from March.
<h3 class="wp-block-heading">Tariffs Slash Producer Prices</h3>
The Producer Price Index fell 0.5% month over month, marking the sharpest decline since April 2020. This was a steep reversal from March's flat reading and missed economists&#8217; expectations for a 0.2% increase.
On a year-over-year basis, producer inflation cooled to 2.4%, down from 3.1% in March and undercutting forecasts of 2.5%.
&#8220;The April decline in the index for final demand is attributable to prices for final demand services, which decreased 0.7%,&#8221; the Bureau of Labor Statistics said.
More than 40% of April's drop in the final demand services index stemmed from a 6.1% decline in margins for machinery and vehicle wholesaling. Additional declines were recorded in portfolio management, food and alcohol wholesaling, system software publishing, traveler accommodations, and airline passenger services.
Core producer prices, which exclude food and energy, dropped 0.4% on the month, wiping out the previous month's 0.4% gain and coming in well below the 0.3% estimate. 
On an annual basis, core PPI rose 3.1%, easing from 4% in March but in line with consensus.
<h3 class="wp-block-heading">Market Reaction: Yields Rise, Stocks Slip</h3>
U.S. stock futures pulled back after a three-day rally. By 8:40 a.m. ET, futures on the S&amp;P 500 were down 0.3%, while Nasdaq 100 futures fell 0.4%.
Meanwhile, the U.S. Dollar Index (DXY) – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – fell to 100.7 levels. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45430835/us-stocks-likely-to-open-lower-after-sp-500s-three-day-winning-streak-many-uncertainties-remain-says-expert">US Stocks Likely To Open Lower After S&amp;P 500&#8217;s Three-Day Winning Streak: &#8216;&#8230;Many Uncertainties Remain,&#8217; Says Expert </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Econ #s

Economics

PowerShares DB US Dollar Index Bullish Fund

Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020

Watching Walmart; During Conf Call, CFO Reportedly Says February Was Softer Than Expected, March Was Back To Norma And April Was Very Strong; We Will Need To Manage Quantity Volumes As We Measure Tariffs

Press Releases

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences

Financing

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

Comments

Praxis Precision Medicine

Noticias

Últimas noticias sobre Praxis Precision Medicine (NASDAQ:PRAX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL